753 results on '"Vassal G."'
Search Results
2. P50 Joint Modelling of Intermediate Longitudinal Biomarkers to Predict Overall Survival in Patients with Solid Tumors
3. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial
4. An academia-driven compassionate use program for patients with recurrent H3K27-altered diffuse midline glioma: a new way to access innovation when clinical trials are lacking
5. Joint adolescent–adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform—ACCELERATE
6. Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
7. The impact of the EU General Data Protection Regulation on childhood cancer research in Europe
8. Clinical, methodology, and patient/carer expert advice in pediatric drug development by conect4children.
9. Nouveaux médicaments contre les cancers pédiatriques : ce qui doit bouger en Europe
10. Multidisciplinarité et formation des spécialistes à l’oncologie et à l’hématologie maligne pédiatrique
11. Accès aux essais précoces de nouveaux médicaments anticancéreux pour les enfants et les adolescents en France
12. INTER-B NHL-RITUX-2010 TRIAL FOR CHILDREN/ADOLESCENTS WITH HIGH-RISK MATURE B-NHL: SAFETY AND EFFICACY IN PATIENTS TREATED WITH RITUXIMAB AND LMB CHEMOTHERAPY
13. 464P Intra-patient (Pt) comparison from larotrectinib (Laro) clinical trials in tropomyosin receptor kinase (TRK) fusion cancer: An expanded dataset
14. Actualités pharmacologiques – le crizotinib (Xalkori®)
15. 468P Real-world safety of trametinib monotherapy or in combination with dabrafenib in children, adolescents, and young adults with relapsed or refractory low-grade glioma (LGG) and high-grade glioma (HGG)
16. Intercontinental collaboration in clinical trials for children and adolescents with cancer—A systematic review by ACCELERATE
17. Target actionability review to evaluate CDK4/6 as a therapeutic target in paediatric solid and brain tumours
18. IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma
19. Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial
20. Dose-finding designs in pediatric phase I clinical trials: Comparison by simulations in a realistic timeline framework
21. The Detection of Transitions in Superconducting Coils
22. Stimulation of tumor growth in vitro and in vivo by Suramin in an experimental model
23. A European paediatric cancer mission: aspiration or reality?
24. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper
25. Access to essential anticancer medicines for children and adolescents in Europe
26. Chemotherapy in osteogenic sarcoma: The experience of the Pediatric Department of the Gustave Roussy Institute
27. Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy
28. More and better cure for an orphan: priorities for future paediatric cancer research in Europe – Meeting report of the EC-funded science-communication project DIRECT “Overcoming Cancer with Research”
29. Imperative of continual support by the European Community for future advances in paediatric oncology in Europe: meeting report of the EC-funded science-communication project DIRECT “Overcoming Cancer with Research”
30. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring
31. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children
32. Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents : ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
33. Pleiotrophin, a candidate gene for poor tumor vasculature and in vivo neuroblastoma sensitivity to irinotecan
34. Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network
35. Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium
36. Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium
37. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa)
38. Human growth hormone gene transfer into tumor cells may improve cancer chemotherapy
39. Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with neuroblastoma and medulloblastoma
40. Thérapies ciblées en oncologie pédiatrique : nouvelle approche thérapeutique
41. Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma
42. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution
43. 604TiP ON-TRK: A non-interventional study of larotrectinib in patients with TRK fusion cancer
44. 542P Growth modulation index (GMI) of larotrectinib versus prior systemic treatments for TRK fusion cancer patients
45. Clinical utility of ctDNA genomic alterations (GA) based on ESMO scale for clinical actionability of molecular targets (ESCAT) in advanced NSCLC
46. A combination of resistance mechanisms is frequent in non-small cell lung cancer (NSCLC) that progressed to EGFR tyrosine kinase inhibitors (TKIs)
47. 2.O.06 ITCC, THE INNOVATIVE THERAPIES FOR CHILDREN WITH CANCER CONSORTIUM: A PARADIGM FOR PAEDIATRIC EARLY DRUG DEVELOPMENT NETWORKS IN EUROPE?
48. 2.O.07 KIDSCANCERKINOME; KINASE DRUG TARGETS IN PAEDIATRIC CANCERS
49. Elevated Plasma Ferritin and Busulfan Pharmacodynamics During High-dose Chemotherapy Regimens in Children with Malignant Solid Tumors
50. O.090 SELECTING NOVEL COMPOUNDS FOR PEDIATRIC MALIGNANCIES USING AFFYMETRIX PROFILES: THE ITCC EXPERIENCE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.